McKesson closes $2.25 billion deal in precision medicine, betting on AI

{
  "signal_id": "1d7313b9-737d-7397-1898-142423821193",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-08-25T13:16:43+00:00",
  "company": {
    "name": "McKesson",
    "domain": "mckesson.com"
  },
  "data": {
    "url": "https://www.boursorama.com/bourse/actualites-amp/mckesson-conclut-un-accord-de-2-25-milliards-de-dollars-dans-le-domaine-de-la-medecine-de-precision-misant-ainsi-sur-la-recherche-clinique-2de6c5f094bf591341f581577605540d",
    "title": "McKesson closes $2.25 billion deal in precision medicine, betting on AI - Boursorama",
    "excerpt": "((Automated translation by Reuters using machine learning and generative AI, please refer to the following disclaimer: https://bit.ly/rtrsauto)) * The deal, valued at approximately $2.25 billion, strengthens McKesson's clinical research and drug launch services * Brian Tyler, McKesson's CEO, says the acquisition strengthens the company's clinical trial execution capabilities * Revenue from the Oncology and Multi-Specialty divisions grew 33% to $14.2 billion in the last quarter (Adds share price movement in paragraph 1 and analyst comments in paragraphs 6, 7 and 9) by Sahil Pandey and Siddhi Mahatole\nMcKesson MCK.N announced on Tuesday its intention to acquire privately held Precision Medicine Group in a transaction valued at approximately $2.25 billion, as part of a long-term strategy to strengthen its high-growth businesses.\nThe U.S. drug distributor is currently overhauling its portfolio by divesting non-strategic assets and streamlining its operations, while investing in areas such as oncology and specialty care to drive long-term growth.\n\"Precision Medicine Group brings complementary capabilities that will enhance our clinical research and commercialization services, strengthen clinical trial execution, and expand our clinical service offerings,\" said Brian Tyler, McKesson's chief executive officer, in a statement.\nBased in Bethesda, Maryland, Precision provides clinical...",
    "summary": "McKesson announced its intention to acquire Precision Medicine Group in a deal valued at approximately $2.25 billion to strengthen its high-growth businesses.",
    "location": "Bethesda, Maryland, USA",
    "planning": true,
    "image_url": "https://www.boursorama.com/bundles/boursoramaui/images/news/trading-news-6.jpg",
    "confidence": 0.95,
    "published_at": "2026-08-25T13:16:43Z",
    "location_data": [
      {
        "city": "Bethesda",
        "state": "Maryland",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-08-25",
    "article_sentence": "McKesson MCK.N announced on Tuesday its intention to acquire privately held Precision Medicine Group in a transaction valued at approximately $2.25 billion, as part of a long-term strategy to strengthen its high-growth businesses.",
    "amount_normalized": 2250000000,
    "related_company_name": "Precision Medicine Group",
    "related_company_domain": "precisionmedicinegrp.com"
  }
}

curl https://signals.autobound.ai/v1/signals/1d7313b9-737d-7397-1898-142423821193 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"mckesson.com","limit":20}'